lupus nephritis/triglyceride

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 28 rezultatus

Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Patients with systemic lupus erythematosus, particularly with lupus nephritis (LN), are at risk of premature cardiovascular (CV) disease. OBJECTIVE To determine the association between immunosuppressive medications, traditional CV risk factors and carotid intima media thickness (CIMT)

Lupus nephritis in males: 8-year experience at Siriraj Hospital.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

During 1984 to 1991, 54 out of 569 lupus nephritis patients at Siriraj Hospital were male (F:M sex ratio = 10:1). Mean age of the males was 29.8 +/- 14.6 years, range 12 to 69. The three most common extrarenal manifestations were anemia, cutaneous, and musculoskeletal involvement (74.5, 51.1, and

Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Twenty-two patients with histologically demonstrated diffuse proliferative lupus nephritis (DPLN) and glomerular thrombosis received a 14-day course of ancrod, followed in most by nitrogen mustard (mechlorethamine hydrochloride) 0.4 mg/kg. Many were referred when renal function was deteriorating

Frequency of Dyslipidemia in patients with Lupus Nephritis.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To determine the frequency of dyslipidemia in patients with lupus nephritis and its association with the degree of proteinuria. METHODS This cross-sectional analytic study included 65 patients who fulfilled the ACR (American College of Rheumatology) criteria for SLE and had renal

Cardiologic abnormalities in patients with long-term lupus nephritis.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

To assess the cardiological status of patients with long-term lupus nephritis we evaluated 30 patients (mean age 43 +/- 11 years) with lupus nephritis lasting from at least 10 years (mean 15 +/- 5 years). At the time of cardiological evaluation the mean plasma creatinine was 132.6 +/- 11.1 mumol/l

The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

There is a high prevalence of hyperuricemia (HUA) in the chronic kidney disease (CKD) population. However, there's a dearth of research on HUA's prevalence, subtypes, early detection, and treatment strategies of HUA in lupus nephritis (LN) patients. The aim of this study is to address these

Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To determine the matrix metalloproteinase-3 (MMP-3) levels in sera from patients with systemic lupus erythematosus (SLE) and to analyse the relationships between MMP-3 and clinical and laboratory features. METHODS Serum MMP-3 levels were measured by an enzyme immunoassay in 124 patients

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Renal involvement is one of the major determinants of the outcome in patients with systemic lupus erythematosus. Renal involvement contributes to both morbidity and mortality of the patients as well as indirectly through side effects of therapy directed at the renal lesions. The aim of

[Lipid profile in patients with systemic lupus erythematosus, with special focus on lipoprotein(a) in lupus nephritis].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Systemic lupus erythematosus (SLE) is a multifactorial polysystemic autoimmune disorder. Although life expectance in SLE has been improved by adequate immune suppressive therapy, the importance of chronic renal failure has not been reduced. Among late complications of the disease accelerated

Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are used as an adjuvant treatment in lupus nephritis (LN) patients with proteinuria. The primary aim of this study was to discover whether ACE inhibitors/ARBs have an atheroprotective effect similar to other,

Evaluation of renal grafts in patients with lupus nephritis as cause of end-stage renal disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Kidney transplantation is the best option in end-stage renal disease (ESRD). For many years patients affected with lupus nephritis have had poor graft results. However, this has been changing over recent years with the development of new immunosuppressive drugs and a better comprehension

Sequential evaluation of clinical and laboratory changes amongst children suffering from lupus nephritis during intermittent intravenous cyclophosphamide therapy.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We prospectively evaluated the efficacy and safety of a 24-month course of intermittent intravenous cyclophosphamide (IC) therapy for children suffering from lupus nephritis soon after the diagnosis of systemic lupus erythematosus (SLE) was made. Eight children with severe lupus nephritis were

Therapeutic Effect of Dendrobium candidum on Lupus Nephritis in Mice.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Dendrobium candidum (D. candimum) widely is a functional drug. The curative effect of D. candidum on lupus nephritis has been studied in vivo. METHODS The DBA/2 and B6D2F1 mice were used for this in vivo experiment. The 50% effective dose (ED50) was used to check the effective

Serum GlycA Level is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Reliable non-invasive biomarkers are needed to assess disease activity and prognosis in patients with systemic lupus erythematosus (SLE). Glycoprotein acetylation (GlycA), a novel biomarker for chronic inflammation, has been reported to be increased in several inflammatory diseases. We

Fish oil in lupus nephritis: clinical findings and methodological implications.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Our objective was to determine the effects of fish oil on renal function, symptoms, and serum lipids in patients with lupus nephritis. A double-blind, randomized crossover trial of fish oil versus placebo (olive oil) was done on 26 patients with confirmed systemic lupus; 21 completed the study.

Ankstesnis
1
2
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais